Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Lung Cancer

Free Subscription Articles published in Cancer Lett Retrieve available abstracts of 75 articles: HTML format

Single Articles

September 2021
1. TANIMURA K, Yamada T, Horinaka M, Katayama Y, et al
   Inhibition of c-Jun N-terminal kinase signaling increased apoptosis and prevented the emergence of ALK-TKI-tolerant cells in ALK-rearranged non-small cell lung cancer.
   Cancer Lett. 2021;522:119-128.
   PubMed     Abstract available
   
   
   
2. XU Y, Chen Y, Yao Y, Xie H, et al
   VIRMA contributes to non-small cell lung cancer progression via N(6)-methyladenosine-dependent DAPK3 post-transcriptional modification.
   Cancer Lett. 2021 Sep 11. pii: S0304-3835(21)00422.
   PubMed     Abstract available
   
   
   
3. WANG J, Dai Z, Miao Y, Zhao T, et al
   Carbon ion ((12)C(6+)) irradiation induces the expression of Klrk1 in lung cancer and optimizes the tumor microenvironment based on the NKG2D/NKG2D-Ls pathway.
   Cancer Lett. 2021;521:178-195.
   PubMed     Abstract available
   
   
   August 2021
4. JIANG Y, Zhan H, Zhang Y, Yang J, et al
   ZIP4 promotes non-small cell lung cancer metastasis by activating snail-N-cadherin signaling axis.
   Cancer Lett. 2021 Aug 24. pii: S0304-3835(21)00420.
   PubMed     Abstract available
   
   
   
5. PARK MS, Yang AY, Lee JE, Kim SK, et al
   GALNT3 suppresses lung cancer by inhibiting myeloid-derived suppressor cell infiltration and angiogenesis in a TNFR and c-MET pathway-dependent manner.
   Cancer Lett. 2021 Aug 17. pii: S0304-3835(21)00404.
   PubMed     Abstract available
   
   
   
6. TAROMI S, Firat E, Simonis A, Braun LM, et al
   Enhanced AC133-specific CAR T cell therapy induces durable remissions in mice with metastatic small cell lung cancer.
   Cancer Lett. 2021 Aug 15. pii: S0304-3835(21)00401.
   PubMed     Abstract available
   
   
   July 2021
7. LIN S, Li Y, Wang D, Huang C, et al
   Fascin promotes lung cancer growth and metastasis by enhancing glycolysis and PFKFB3 expression.
   Cancer Lett. 2021;518:230-242.
   PubMed     Abstract available
   
   
   
8. JIN M, Li G, Liu W, Wu X, et al
   Cigarette smoking induces aberrant N(6)-methyladenosine of DAPK2 to promote non-small cell lung cancer progression by activating NF-kappaB pathway.
   Cancer Lett. 2021;518:214-229.
   PubMed     Abstract available
   
   
   
9. HUANG J, Tian F, Song Y, Cao M, et al
   A feedback circuit comprising EHD1 and 14-3-3zeta sustains beta-catenin/c-Myc-mediated aerobic glycolysis and proliferation in non-small cell lung cancer.
   Cancer Lett. 2021;520:12-25.
   PubMed     Abstract available
   
   
   June 2021
10. ZHANG J, Zeng Y, Xing Y, Li X, et al
    Myristoylation-mediated phase separation of EZH2 compartmentalizes STAT3 to promote lung cancer growth.
    Cancer Lett. 2021 Jun 5. pii: S0304-3835(21)00266.
    PubMed     Abstract available
    
    
    May 2021
11. JIANG ZB, Wang WJ, Xu C, Xie YJ, et al
    Luteolin and its derivative apigenin suppress the inducible PD-L1 expression to improve anti-tumor immunity in KRAS-mutant lung cancer.
    Cancer Lett. 2021;515:36-48.
    PubMed     Abstract available
    
    
    
12. ZHANG H, Jiang H, Zhu L, Li J, et al
    Cancer-associated fibroblasts in non-small cell lung cancer: Recent advances and future perspectives.
    Cancer Lett. 2021 May 18. pii: S0304-3835(21)00224.
    PubMed     Abstract available
    
    
    April 2021
13. WANG J, Hu T, Wang Q, Chen R, et al
    Repression of the AURKA-CXCL5 axis induces autophagic cell death and promotes radiosensitivity in non-small-cell lung cancer.
    Cancer Lett. 2021;509:89-104.
    PubMed     Abstract available
    
    
    March 2021
14. LIN CY, Huang KY, Lin YC, Yang SC, et al
    Vorinostat combined with brigatinib overcomes acquired resistance in EGFR-C797S-mutated lung cancer.
    Cancer Lett. 2021;508:76-91.
    PubMed     Abstract available
    
    
    
15. LEE S, Hong JH, Kim JS, Yoon JS, et al
    Cancer-associated fibroblasts activated by miR-196a promote the migration and invasion of lung cancer cells.
    Cancer Lett. 2021;508:92-103.
    PubMed     Abstract available
    
    
    
16. MA Y, Wang L, He F, Yang J, et al
    LACTB suppresses melanoma progression by attenuating PP1A and YAP interaction.
    Cancer Lett. 2021 Mar 3. pii: S0304-3835(21)00101.
    PubMed     Abstract available
    
    
    
17. TRAVER G, Sekhar KR, Crooks PA, Keeney DS, et al
    Targeting NPM1 in irradiated cells inhibits NPM1 binding to RAD51, RAD51 foci formation and radiosensitizes NSCLC.
    Cancer Lett. 2021;500:220-227.
    PubMed     Abstract available
    
    
    February 2021
18. DANG N, Lin Y, Waer M, Sprangers B, et al
    Immunization with alloantibodies-covered melanoma cells induces regional antitumor effects that become systemic when combined with 5-FU treatment.
    Cancer Lett. 2021;503:151-162.
    PubMed     Abstract available
    
    
    January 2021
19. LI Y, Chen Y, Miao L, Wang Y, et al
    Stress-induced upregulation of TNFSF4 in cancer-associated fibroblast facilitates chemoresistance of lung adenocarcinoma through inhibiting apoptosis of tumor cells.
    Cancer Lett. 2021;497:212-220.
    PubMed     Abstract available
    
    
    
20. WANG J, Sun T, Meng Z, Wang L, et al
    XPO1 inhibition synergizes with PARP1 inhibition in small cell lung cancer by targeting nuclear transport of FOXO3a.
    Cancer Lett. 2021 Jan 22. pii: S0304-3835(21)00024.
    PubMed     Abstract available
    
    
    
21. LI X, Chen M, Lu W, Tang J, et al
    Targeting FAPalpha-expressing tumor-associated mesenchymal stromal cells inhibits triple-negative breast cancer pulmonary metastasis.
    Cancer Lett. 2021 Jan 19. pii: S0304-3835(21)00029.
    PubMed     Abstract available
    
    
    
22. TANG S, Li S, Liu T, He Y, et al
    MicroRNAs: Emerging oncogenic and tumor-suppressive regulators, biomarkers and therapeutic targets in lung cancer.
    Cancer Lett. 2021;502:71-83.
    PubMed     Abstract available
    
    
    
23. ZHOU S, Xie J, Huang Z, Deng L, et al
    Anti-PD-(L)1 immunotherapy for brain metastases in non-small cell lung cancer: Mechanisms, advances, and challenges.
    Cancer Lett. 2021 Jan 12. pii: S0304-3835(21)00008.
    PubMed     Abstract available
    
    
    
24. GRILLO E, Corsini M, Ravelli C, di Somma M, et al
    A novel variant of VEGFR2 identified by a pan-cancer screening of recurrent somatic mutations in the catalytic domain of tyrosine kinase receptors enhances tumor growth and metastasis.
    Cancer Lett. 2021;496:84-92.
    PubMed     Abstract available
    
    
    December 2020
25. LO SARDO F, Pulito C, Sacconi A, Korita E, et al
    YAP/TAZ and EZH2 synergize to impair tumor suppressor activity of TGFBR2 in non-small cell lung cancer.
    Cancer Lett. 2020 Dec 6. pii: S0304-3835(20)30636.
    PubMed     Abstract available
    
    
    
26. YAO S, Shi F, Mu N, Li X, et al
    Angio-associated migratory cell protein (AAMP) interacts with cell division cycle 42 (CDC42) and enhances migration and invasion in human non-small cell lung cancer cells.
    Cancer Lett. 2020 Dec 3. pii: S0304-3835(20)30648.
    PubMed     Abstract available
    
    
    
27. ZHOU L, Xu Q, Huang L, Jin J, et al
    Low-dose carboplatin reprograms tumor immune microenvironment through STING signaling pathway and synergizes with PD-1 inhibitors in lung cancer.
    Cancer Lett. 2020 Dec 2. pii: S0304-3835(20)30647.
    PubMed     Abstract available
    
    
    
28. CHEN D, Wu X, Chen Y, Chen C, et al
    Comment on 'Clinical significance and inflammatory landscapes of a novel recurrence associated immune signature in early-stage lung adenocarcinoma'.
    Cancer Lett. 2020;494:17.
    PubMed    
    
    
    
29. SUN N, Zhang C, He J
    Response to comment on 'Clinical significance and inflammatory landscapes of a novel recurrence-associated immune signature in early-stage lung adenocarcinoma'.
    Cancer Lett. 2020;494:5-6.
    PubMed    
    
    
    November 2020
30. ZHENG Y, Wang Z, Wei S, Liu Z, et al
    Epigenetic silencing of chemokine CCL2 represses macrophage infiltration to potentiate tumor development in small cell lung cancer.
    Cancer Lett. 2020 Nov 28. pii: S0304-3835(20)30632.
    PubMed     Abstract available
    
    
    
31. XIE J, Yang P, Lin HP, Li Y, et al
    Integrin alpha4 up-regulation activates the hedgehog pathway to promote arsenic and benzo[alpha]pyrene co-exposure-induced cancer stem cell-like property and tumorigenesis.
    Cancer Lett. 2020;493:143-155.
    PubMed     Abstract available
    
    
    
32. YAO C, Su L, Zhang F, Zhu X, et al
    Thevebioside, the active ingredient of traditional Chinese medicine, promotes ubiquitin-mediated SRC-3 degradation to induce NSCLC cells apoptosis.
    Cancer Lett. 2020;493:167-177.
    PubMed     Abstract available
    
    
    
33. YUAN J, Xing H, Li Y, Song Y, et al
    EPB41 suppresses the Wnt/beta-catenin signaling in non-small cell lung cancer by sponging ALDOC.
    Cancer Lett. 2020 Nov 24. pii: S0304-3835(20)30622.
    PubMed     Abstract available
    
    
    
34. SHIH CT, Shiau CW, Chen YL, Chen LJ, et al
    TD-92, a novel erlotinib derivative, depletes tumor-associated macrophages in non-small cell lung cancer via down-regulation of CSF-1R and enhances the anti-tumor effects of anti-PD-1.
    Cancer Lett. 2020 Nov 21. pii: S0304-3835(20)30577.
    PubMed     Abstract available
    
    
    
35. LI J, Gao A, Zhang F, Wang S, et al
    ILT3 promotes tumor cell motility and angiogenesis in non-small cell lung cancer.
    Cancer Lett. 2020 Nov 2. pii: S0304-3835(20)30582.
    PubMed     Abstract available
    
    
    October 2020
36. PHAM K, Huynh D, Le L, Delitto D, et al
    E-cigarette promotes breast carcinoma progression and lung metastasis: Macrophage-tumor cells crosstalk and the role of CCL5 and VCAM-1.
    Cancer Lett. 2020;491:132-145.
    PubMed     Abstract available
    
    
    
37. MULET M, Zamora C, Porcel JM, Nieto JC, et al
    Platelet factor 4 regulates T cell effector functions in malignant pleural effusions.
    Cancer Lett. 2020;491:78-86.
    PubMed     Abstract available
    
    
    
38. HAQUE A, Rahman MA, Fuchs JR, Chen Z, et al
    Corrigendum to "FLLL12 induces apoptosis in lung cancer cells through a p53/p73-independent but death receptor 5-dependent pathway" [Canc. Lett. 363 (2015) 166-175].
    Cancer Lett. 2020 Oct 20. pii: S0304-3835(20)30395.
    PubMed    
    
    
    
39. MIYASHITA N, Horie M, Mikami Y, Urushiyama H, et al
    ASCL1 promotes tumor progression through cell-autonomous signaling and immune modulation in a subset of lung adenocarcinoma.
    Cancer Lett. 2020;489:121-132.
    PubMed     Abstract available
    
    
    September 2020
40. PARK S, Kim TM, Cho SY, Kim S, et al
    Combined blockade of polo-like kinase and pan-RAF is effective against NRAS-mutant non-small cell lung cancer cells.
    Cancer Lett. 2020;495:135-144.
    PubMed     Abstract available
    
    
    
41. QUAN C, Chen Y, Wang X, Yang D, et al
    Loss of histone lysine methyltransferase EZH2 confers resistance to tyrosine kinase inhibitors in non-small cell lung cancer.
    Cancer Lett. 2020 Sep 10. pii: S0304-3835(20)30465.
    PubMed     Abstract available
    
    
    
42. MAHMUD F, Deng S, Chen H, Miller DD, et al
    Orally available tubulin inhibitor VERU-111 enhances antitumor efficacy in paclitaxel-resistant lung cancer.
    Cancer Lett. 2020 Sep 10. pii: S0304-3835(20)30466.
    PubMed     Abstract available
    
    
    
43. ZENG Y, Jie X, Wu B, Wu G, et al
    IQGAP3 interacts with Rad17 to recruit the Mre11-Rad50-Nbs1 complex and contributes to radioresistance in lung cancer.
    Cancer Lett. 2020 Sep 4. pii: S0304-3835(20)30456.
    PubMed     Abstract available
    
    
    August 2020
44. CHEN C, Liu WR, Zhang B, Zhang LM, et al
    LncRNA H19 downregulation confers erlotinib resistance through upregulation of PKM2 and phosphorylation of AKT in EGFR-mutant lung cancers.
    Cancer Lett. 2020;486:58-70.
    PubMed     Abstract available
    
    
    
45. WANG C, Tan S, Li J, Liu WR, et al
    CircRNAs in lung cancer - Biogenesis, function and clinical implication.
    Cancer Lett. 2020 Aug 26. pii: S0304-3835(20)30427.
    PubMed     Abstract available
    
    
    
46. SHOU J, You L, Yao J, Xie J, et al
    Corrigendum to "Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3" [Canc Lett 379 (2016) 124-133].
    Cancer Lett. 2020;493:13-15.
    PubMed    
    
    
    
47. TIAN D, Tang J, Geng X, Li Q, et al
    Targeting UHRF1-dependent DNA repair selectively sensitizes KRAS mutant lung cancer to chemotherapy.
    Cancer Lett. 2020 Aug 16. pii: S0304-3835(20)30421.
    PubMed     Abstract available
    
    
    
48. CASAL-MOURINO A, Ruano-Ravina A, Torres-Duran M, Parente-Lamelas I, et al
    Corrigendum to "Lung cancer survival in never-smokers and exposure to residential radon: Results of the LCRINS study" [Canc. Lett. 487 (2020) 21-26].
    Cancer Lett. 2020;493:10.
    PubMed    
    
    
    
49. TEOH ST, Ogrodzinski MP, Lunt SY
    UDP-glucose 6-dehydrogenase knockout impairs migration and decreases in vivo metastatic ability of breast cancer cells.
    Cancer Lett. 2020 Aug 5. pii: S0304-3835(20)30388.
    PubMed     Abstract available
    
    
    
50. WANG D, Cong J, Fu B, Zheng X, et al
    Immunogenic chemotherapy effectively inhibits KRAS-Driven lung cancer.
    Cancer Lett. 2020 Aug 3. pii: S0304-3835(20)30399.
    PubMed     Abstract available
    
    
    
51. GALLAND S, Martin P, Fregni G, Letovanec I, et al
    Attenuation of the pro-inflammatory signature of lung cancer-derived mesenchymal stromal cells by statins.
    Cancer Lett. 2020;484:50-64.
    PubMed     Abstract available
    
    
    July 2020
52. ZHOU W, Liu Y, Gao Y, Cheng Y, et al
    MICAL2 is a novel nucleocytoplasmic shuttling protein promoting cancer invasion and growth of lung adenocarcinoma.
    Cancer Lett. 2020;483:75-86.
    PubMed     Abstract available
    
    
    
53. JIN R, Wang X, Zang R, Liu C, et al
    Desmoglein-2 modulates tumor progression and osimertinib drug resistance through the EGFR/Src/PAK1 pathway in lung adenocarcinoma.
    Cancer Lett. 2020;483:46-58.
    PubMed     Abstract available
    
    
    
54. XU L, Hu H, Zheng LS, Wang MY, et al
    ETV4 is a theranostic target in clear cell renal cell carcinoma that promotes metastasis by activating the pro-metastatic gene FOSL1 in a PI3K-AKT dependent manner.
    Cancer Lett. 2020;482:74-89.
    PubMed     Abstract available
    
    
    
55. OGAWA K, Lin Q, Li L, Bai X, et al
    Prometastatic secretome trafficking via exosomes initiates pancreatic cancer pulmonary metastasis.
    Cancer Lett. 2020;481:63-75.
    PubMed     Abstract available
    
    
    June 2020
56. YIN H, Wang X, Zhang X, Zeng Y, et al
    UBE2T promotes radiation resistance in non-small cell lung cancer via inducing epithelial-mesenchymal transition and the ubiquitination-mediated FOXO1 degradation.
    Cancer Lett. 2020 Jun 23. pii: S0304-3835(20)30331.
    PubMed     Abstract available
    
    
    
57. HUANG XH, Yan X, Zhang QH, Hong P, et al
    Direct targeting of HSP90 with daurisoline destabilizes beta-catenin to suppress lung cancer tumorigenesis.
    Cancer Lett. 2020 Jun 13. pii: S0304-3835(20)30286.
    PubMed     Abstract available
    
    
    
58. ZHANG C, Zhang Z, Zhang G, Zhang Z, et al
    Clinical significance and inflammatory landscapes of a novel recurrence-associated immune signature in early-stage lung adenocarcinoma.
    Cancer Lett. 2020;479:31-41.
    PubMed     Abstract available
    
    
    
59. HUANG F, Ma G, Zhou X, Zhu X, et al
    Depletion of LAMP3 enhances PKA-mediated VASP phosphorylation to suppress invasion and metastasis in esophageal squamous cell carcinoma.
    Cancer Lett. 2020;479:100-111.
    PubMed     Abstract available
    
    
    May 2020
60. MOURINO AC, Ruano-Ravina A, Torres-Duran M, Parente-Lamelas I, et al
    Lung cancer survival in never-smokers and exposure to residential radon: Results of the LCRINS study.
    Cancer Lett. 2020 May 23. pii: S0304-3835(20)30284.
    PubMed     Abstract available
    
    
    
61. ZHAO Z, Zhang N, Li A, Zhou B, et al
    Insulin-like growth factor-1 receptor induces immunosuppression in lung cancer by upregulating B7-H4 expression through the MEK/ERK signaling pathway.
    Cancer Lett. 2020 May 14. pii: S0304-3835(20)30199.
    PubMed     Abstract available
    
    
    
62. YANG YF, Wang YY, Hsiao M, Lo S, et al
    IMPAD1 functions as mitochondrial electron transport inhibitor that prevents ROS production and promotes lung cancer metastasis through the AMPK-Notch1-HEY1 pathway.
    Cancer Lett. 2020 May 14. pii: S0304-3835(20)30227.
    PubMed     Abstract available
    
    
    April 2020
63. ACHYUT BR, Zhang H, Angara K, Mivechi NF, et al
    Oncoprotein GT198 vaccination delays tumor growth in MMTV-PyMT mice.
    Cancer Lett. 2020;476:57-66.
    PubMed     Abstract available
    
    
    
64. CHEN J, Liu A, Lin Z, Wang B, et al
    Downregulation of the Circadian Rhythm Regulator HLF Promotes Multiple-Organ Distant Metastases in Non-Small Cell Lung Cancer through PPAR/NF-kappaB Signaling.
    Cancer Lett. 2020 Apr 11. pii: S0304-3835(20)30184.
    PubMed     Abstract available
    
    
    
65. WANG J, Li X, Chen H
    Organoid models in lung regeneration and cancer.
    Cancer Lett. 2020;475:129-135.
    PubMed     Abstract available
    
    
    
66. KIM DH, Park S, Kim H, Choi YJ, et al
    Tumor-derived exosomal miR-619-5p promotes tumor angiogenesis and metastasis through the inhibition of RCAN1.4.
    Cancer Lett. 2020;475:2-13.
    PubMed     Abstract available
    
    
    
67. WANG J, Wu X, Dai W, Li J, et al
    The CCDC43-ADRM1 axis regulated by YY1, promotes proliferation and metastasis of gastric cancer.
    Cancer Lett. 2020 Apr 8. pii: S0304-3835(20)30159.
    PubMed     Abstract available
    
    
    
68. KUO CL, Chou HY, Chiu YC, Cheng AN, et al
    Mitochondrial oxidative stress by Lon-PYCR1 maintains an immunosuppressive tumor microenvironment that promotes cancer progression and metastasis.
    Cancer Lett. 2020;474:138-150.
    PubMed     Abstract available
    
    
    
69. ALMACELLAS-RABAIGET O, Monaco P, Huertas-Martinez J, Garcia-Monclus S, et al
    LOXL2 promotes oncogenic progression in alveolar rhabdomyosarcoma independently of its catalytic activity.
    Cancer Lett. 2020;474:1-14.
    PubMed     Abstract available
    
    
    March 2020
70. VANBERVLIET-DEFRANCE B, Delaunay T, Daunizeau T, Kepenekian V, et al
    Cisplatin unleashes Toll-like receptor 3-mediated apoptosis through the downregulation of c-FLIP in malignant mesothelioma.
    Cancer Lett. 2020;472:29-39.
    PubMed     Abstract available
    
    
    January 2020
71. SEIDL C, Panzitt K, Bertsch A, Brcic L, et al
    MicroRNA-182-5p regulates hedgehog signaling pathway and chemosensitivity of cisplatin-resistant lung adenocarcinoma cells via targeting GLI2.
    Cancer Lett. 2020;469:266-276.
    PubMed     Abstract available
    
    
    
72. ZHANG L, Zhang X, Liu Y, Zhang T, et al
    PD-L1(+) aneuploid circulating tumor endothelial cells (CTECs) exhibit resistance to the checkpoint blockade immunotherapy in advanced NSCLC patients.
    Cancer Lett. 2020;469:355-366.
    PubMed     Abstract available
    
    
    September 2019
73. ZOU H, Chen H, Zhou Z, Wan Y, et al
    ATXN3 promotes breast cancer metastasis by deubiquitinating KLF4.
    Cancer Lett. 2019 Sep 26. pii: S0304-3835(19)30484.
    PubMed     Abstract available
    
    
    May 2019
74. FLAHERTY RL, Intabli H, Falcinelli M, Bucca G, et al
    Stress hormone-mediated acceleration of breast cancer metastasis is halted by inhibition of nitric oxide synthase.
    Cancer Lett. 2019 May 24. pii: S0304-3835(19)30322.
    PubMed     Abstract available
    
    
    
75. LI Y, Acharya G, Elahy M, Xin H, et al
    The Anthelmintic Flubendazole Blocks Human Melanoma Growth and Metastasis and Suppresses Programmed Cell Death Protein-1 and Myeloid-Derived Suppressor Cell Accumulation.
    Cancer Lett. 2019 May 22. pii: S0304-3835(19)30321.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: